The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model

被引:32
|
作者
Caso, Jorge [1 ]
Masko, Elizabeth M. [1 ]
Thomas, Jean A., II [1 ]
Poulton, Susan H. [1 ]
Dewhirst, Mark [2 ]
Pizzo, Salvatore V. [3 ]
Freedland, Stephen J. [1 ,3 ,4 ]
机构
[1] Duke Univ, Med Ctr, Dept Surg, Div Urol Surg,Duke Prostate Ctr, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[4] Durham Vet Adm Hosp, Dept Surg, Durham, NC USA
来源
PROSTATE | 2013年 / 73卷 / 05期
基金
美国国家卫生研究院;
关键词
prostate cancer; diet; low-carbohydrate; castration; insulin; IGF-1; LOW-FAT DIET; ANDROGEN DEPRIVATION THERAPY; IGF-I; CARDIOVASCULAR-DISEASE; SERUM-INSULIN; FACTOR AXIS; RISK; MEN; PATTERNS; EXERCISE;
D O I
10.1002/pros.22586
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND No- and low-carbohydrate diets delay tumor growth compared to western diet (WD) in prostate cancer (PCa) xenograft studies. The effect of these diets in concert with androgen deprivation is unknown. METHODS A total of 160 male SCID mice were injected with 1x 105 LAPC-4 human PCa cells. Of these, 150 mice were castrated and randomized to an ad libitum WD or fed via a paired-feeding protocol with a no-carbohydrate ketogenic diet (NCKD), 10% carbohydrate diet, or 20% carbohydrate diet. The remaining 10 mice were not castrated and were fed an ad libitum WD. The mice were sacrificed once volumes reached 1,000mm3 and survival tested using the log-rank test. Serum from the median surviving 8mice/group was assayed for insulin, IGF-1, and IGFBP-3. RESULTS Body weights were roughly equal among groups. The 10 non-castrated mice experienced accelerated tumor growth. Among castrated mice, WD had the most rapid tumor growth; 20% carbohydrate diet the slowest (P=0.046). Survival was not significantly different among the various carbohydrate restricted groups (P=0.51). When pooled, there was a non-significant trend (P=0.11) in improved survival among the carbohydrate restricted diets versus WD. No significant difference in serum insulin, IGF-1, and IGFBP-3 levels was noted among all groups at pre-randomization or at sacrifice. CONCLUSIONS A 20% carbohydrate diet slowed tumor growth versus a WD. Though the benefit of carbohydrate restriction was somewhat less than in prior studies in non-castrate mice, these data still suggest diets achievable in humans may play a role in PCa management. Prostate 73: 449454, 2013. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:449 / 454
页数:6
相关论文
共 50 条
  • [31] The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer
    Canesin, Giacomo
    Evans-Axelsson, Susan
    Hellsten, Rebecka
    Sterner, Olov
    Krzyzanowska, Agnieszka
    Andersson, Tommy
    Bjartell, Anders
    EUROPEAN UROLOGY, 2016, 69 (03) : 400 - 404
  • [32] Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis
    Freedland, Stephen J.
    Mavropoulos, John
    Wang, Amy
    Darshan, Medha
    Demark-Wahnefried, Wendy
    Aronson, William J.
    Cohen, Pinchas
    Hwang, David
    Peterson, Bercedis
    Fields, Timothy
    Pizzo, Salvatore V.
    Isaacs, William B.
    PROSTATE, 2008, 68 (01): : 11 - 19
  • [33] Tumor promoting effect of spheroids in an orthotopic prostate cancer mouse model
    Bastian, Julius Lars Daniel
    Zeuschner, Philip
    Stoeckle, Michael
    Junker, Kerstin
    Linxweiler, Johannes
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [34] Fucoxanthin inhibits tumor growth of pancreatic cancer in a patient-derived xenograft mouse model
    Terasaki, Masaru
    Tanaka, Takuji
    Yagishita, Shigehiro
    Hamada, Akinobu
    Sakamoto, Yasunari
    Hijioka, Susumu
    Morizane, Chigusa
    Takahashi, Mami
    CANCER SCIENCE, 2024, 115 : 638 - 638
  • [35] Cancer-associated fibroblasts stimulate tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model
    Linxweiler, Johannes
    Hammer, Markus
    Koerbel, Christina
    Mueller, Andreas
    Stoeckle, Michael
    Menger, Michael D.
    Junker, Kerstin
    Saar, Matthias
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Sorafenib inhibits tumor development and growth in a transgenic mouse model of prostate cancer
    Uemura, Hirotsugu
    Hatanaka, Yuji
    Izumi, Ayaka
    Okazaki, Erina
    Doi, Makiko
    Tanaka, Motoyoshi
    Yamamoto, Yutaka
    Shimizu, Nobutaka
    Yoshimura, Kazuhiro
    Nozawa, Masahiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    De Velasco, Marco A.
    CANCER RESEARCH, 2011, 71
  • [37] Tumor immunotherapy in a mouse model of prostate cancer
    Grant, JF
    Ratliff, TL
    FASEB JOURNAL, 2004, 18 (04): : A60 - A60
  • [38] The effects of glycemic index on prostate cancer progression in a xenograft mouse model
    Gloria Cecilia Galván
    Everardo Macias
    Sergio Sanders
    Adela Ramirez-Torres
    Shannon Stock
    Sungyong You
    Celine E. Riera
    Patrick Tamukong
    Stephanie A. Smith-Warner
    Jeanine M. Genkinger
    Daniel J. Luthringer
    Michael R. Freeman
    Stephen J. Freedland
    Prostate Cancer and Prostatic Diseases, 2024, 27 : 348 - 354
  • [39] Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer
    Daniel Eberli
    Benedikt Kranzbühler
    Lukas Prause
    Valentin Baumgartner
    Sheryl Preda
    Rosa Sousa
    Fabienne Lehner
    Souzan Salemi
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3351 - 3360
  • [40] Apalutamide and autophagy inhibition in xenograft mouse model of human prostate cancer
    Salemi, S.
    Kranzbuhler, B.
    Prause, L.
    Baumgartner, V.
    Eberli, D.
    EUROPEAN UROLOGY, 2021, 79 : S607 - S607